Skip to search formSkip to main contentSkip to account menu

rifametane

Known as: 3-(((1-(diethylamino)ethylidene)hydrazono)methyl)rifamycin, 3-((1-diethylaminoethylidene)azinomethyl)rifamycin SV, 3-azinomethyl-rifamycin 
A semisynthetic derivative of rifamycin with a longer biological half-life than rifampicin.
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Rifamycins

Narrower (1)

SPA-S 565

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Pharmacokinetics and Tissue Distribution of Rifametane, a New 3-Azinomethyl-rifamycin Derivative, in Several Animal Species
Summary Single and repeated dose experiments in mice, rats, dogs and monkeys are reported in this study to assess the… 
1999
1999
Phase I Pharmacokinetic Study of a New 3-Azinomethyl-Rifamycin (Rifametane) as Compared to Rifampicin
An open randomized cross-over study was conducted in 8 healthy male volunteers to study the pharmacokinetic pattern and the… 
1998
1998
Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin.
The pharmacokinetics and tolerance of a single oral dose (150 mg) of a new 3-azinomethyl rifamycin (SPA-S-565, USAN rifametane… 
1988
1988
The antibacterial activity of a new 3-azinomethyl-rifamycin.
The new 3-azinomethyl-rifamycin, SPA-S-565, was shown to exert an effective antibacterial activity in vitro comparable to that of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)